Acromegaly患者に於ける各種薬物負荷による血漿成長ホルモンの反応性についての検討

概要

論文の詳細を見る
Growth hormone (GH) responses to L-dopa, 2-Br-α-ergocryptine (CB-154), thyrotropin-releasing hormone (TRH), luteinizing hormone-releasing hormone (LH-RH), glucagon and glucose were investigated in six patients with active acromegaly. The following results were obtained. 1) Subcutaneous injection of 1 mg glucagon caused a clear-cut decrease in plasma GH levels in 5 out of 6 active acromegalic patients at 30 minutes after the injection. In 2 out of 6 patients a rebound of plasma GH was observed. 2) In three out of six patients with active acromegaly, oral administration of 0. 5 g L-dopa caused a significant suppression of plasma GH levels. 3) CB-154 (2. 5 mg) administered orally elicited a marked decrease in plasma G11 levels in the same three patients who showed a significant suppressive GH response to L-dopa, and the inhibitory effect of CB-154 on GH secretion lasted for 6 hours. These patients who had a GH response to L-dopa or CB-154 were named "responders". 4) Intravenous administration of TRH resulted in a significant increase in plasma GH in 4 patients 3 of whom were responders and the other a non-responder. 5) Pretreatment with CB-154 did not modify the TRH-induced GH increase in all patients who had a positive response to TRH. 6) A significant increase in plasma GH was elicited by the intravenous injection of 100 μg LH-RH in 3 out of 6 patients with acromegaly. 7) When oral administration of CB-154 had been given 2 hours before LH-RH, the GH response to LH-RH was blunted in two of three patients who had a LH-RH-induced increase in plasma GH levels.
日本内分泌学会の論文

Acromegaly患者に於ける各種薬物負荷による血漿成長ホルモンの反応性についての検討

スポンサーリンク

概要

著者

関連論文

スポンサーリンク